Bayer's Kidney Data Look Strong. The Earnings Test Still Lands on November 3.

Bayer has fresh clinical evidence to talk about, and a set of analyst ratings that remain firmly in positive territory. What it does not yet have is proof that either will translate into the kind of earnings stability investors are waiting for. That gap is the real story heading into the company's third-quarter update on November 3, when management is also scheduled to provide information for investors.

The medical news arrived first. At ASN Kidney Week 2026, Bayer presented late-breaking poster results from the Phase III FIND-CKD trial, which examined patients with chronic kidney disease but without diabetes. According to the company, the data showed consistent effects on proteinuria and on the decline of kidney function across the patient groups studied. In the FSGS cohort, the UACR value fell 40% versus placebo after twelve months, while UPCR dropped 41%. Among IgAN patients, UPCR declined 51% against placebo.

Those numbers are more than a routine progress note. They span different patient populations and give the Finerenone discussion a firmer footing. Yet a percentage reduction in a urine protein marker is not a revenue line. Nothing in the disclosed figures allows an observer to derive a specific sales trajectory or an incremental profit contribution. Anyone building a case on Finerenone is valuing a prospect, not a quantified improvement in results.

Two Sets of Analysts, One Unchanged Message

The ratings backdrop offers a useful counterweight—and a reminder of its own limits. JPMorgan kept Bayer at "Overweight" on October 16 with a price target of 61 euros. UBS stayed at "Buy" on October 15 with a target of 62 euros. Neither move was an upgrade. Both express a constructive long-term view rather than a fresh endorsement of the business as it stands.

JPMorgan's underlying assumptions, as reported in the media, are worth separating from the headline rating. The firm reportedly expected revenues roughly 2% above consensus but EBITDA about 6% below it, while anticipating confirmation of the annual outlook. That combination captures the tension precisely: a positive verdict on Bayer does not automatically mean unclouded near-term profit prospects.

Should investors sell immediately? Or is it worth buying Bayer?

There is a further wrinkle. Media reports on October 13 indicated that analyst estimates for Bayer's earnings per share had fallen compared with the start of August. That makes the bottom line the central yardstick for the upcoming release. A figure that clears reduced expectations is not the same thing as an improvement over earlier periods, and the two should not be conflated. The order of scrutiny matters: operating performance first, the expectations derived from it second, and only then a judgment on whether the bullish targets carry more weight.

A Regulatory Step, Not a Green Light

Alongside the study data, Bayer has made procedural headway with US regulators. Roughly two weeks ago, the FDA accepted the company's supplemental application for Finerenone in chronic kidney disease without diabetes, a filing built on FIND-CKD. Acceptance is not approval. For the optimistic case it represents another step through the regulatory process, not a secured commercial success—and it does nothing to substitute for confirmation on the operating side.

The picture is complicated further by a decision in Germany. On October 15, the Gemeinsame Bundesausschuss concluded on the benefit assessment of Finerenone in symptomatic chronic heart failure with LVEF ? 40%: "Ein Zusatznutzen ist nicht belegt"—no added benefit has been demonstrated. That ruling concerns a different indication from the kidney data presented this week. It does not invalidate the FIND-CKD results, just as those subgroup findings cannot override the heart-failure verdict. For investors, keeping the two apart is essential: strong data in one patient group does not resolve every valuation question attached to a drug.

The Farm Economy Is Sending Its Own Signal

Pressure from agriculture deserves equal attention. FMC jolted the sector on October 15 with a sharp cut to its outlook, and media reports said the announcement weighed on Bayer as well. No one can infer the size of any potential hit to Bayer from that move, nor explain every subsequent share-price swing by pointing to it.

The broader European farming backdrop adds to the caution. A study commissioned by Bayer, published roughly a week ago, found that the region's production growth in the EU and the United Kingdom trails that of major agricultural markets, with geopolitical and climatic strains intensifying the challenge. None of this proves a specific earnings miss at Bayer. It does argue against simply assuming the agricultural environment will ease.

What November 3 Has to Settle

Two scenarios now hang on the same date. In the brighter one, the consistent FIND-CKD subgroup findings entrench confidence in Finerenone's medical potential, the confirmed annual outlook frames the current business, and the interplay of results across patient groups—rather than any single percentage—carries the valuation. In the darker one, the medical story convinces while the operating result deteriorates more than expected, and near-term profit worries drown out the clinical signals.

The quarterly statement will not settle the scientific question. It can, however, show how sturdy the economic framework is around Bayer's pipeline. Whether the reduced EPS estimates prove durable, or whether further downward revisions follow, is the test that matters. A price target alone answers none of it.

Ad

Bayer Stock: New Analysis - 23 October

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...